Skip to content

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
PreclinicalGrowth HormoneSubQDailyPartial data

Tesamorelin + Ipamorelin

Stack combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for amplified GH pulses and targeted visceral fat reduction.

§ 01   Overview

Overview

Stack combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for amplified GH pulses and targeted visceral fat reduction.

Stack used in compounding. Tesamorelin alone has FDA data; the combination does not.

§ 02   Mechanism

Mechanism of action

Tesamorelin provides sustained GHRH receptor activation while Ipamorelin adds a ghrelin receptor pulse, amplifying endogenous GH release.

  • 01Visceral fat reduction (Tesamorelin) + GH pulse amplification (Ipamorelin)
  • 02Favorable body composition in users

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
Combo vial
BAC Water
2 ml BAC water
Dose Range
10 – 20 units (0.1 – 0.2 ml)
Route
SubQ
Timing
Before bed
Frequency
Daily
Cycle
8–12 weeks

§ 04   Evidence

Evidence & research

Preclinical

Stack used in compounding. Tesamorelin alone has FDA data; the combination does not.

FDA Status

Components: Tesamorelin FDA-approved; Ipamorelin not.

§ 05   Stacks

Common stacks

§ 06   News

In the news

1 article from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Injection site reactions
  • 02Elevated IGF-1

Contraindications

None specified.

§ 10   Questions

Tesamorelin + Ipamorelin FAQ

What is Tesamorelin + Ipamorelin?
Stack combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for amplified GH pulses and targeted visceral fat reduction. Tesamorelin provides sustained GHRH receptor activation while Ipamorelin adds a ghrelin receptor pulse, amplifying endogenous GH release.
What is Tesamorelin + Ipamorelin used for?
Reported uses include visceral fat reduction (tesamorelin) + gh pulse amplification (ipamorelin) and favorable body composition in users. Evidence strength is rated Preclinical — see the evidence section for detail.
How is Tesamorelin + Ipamorelin dosed?
Commonly referenced dosing is 10 – 20 units (0.1 – 0.2 ml), typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.
How do you reconstitute Tesamorelin + Ipamorelin?
For Tesamorelin + Ipamorelin, vials commonly come in Combo vial and a common reconstitution is 2 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
What are the side effects of Tesamorelin + Ipamorelin?
Commonly reported side effects include injection site reactions and elevated igf-1. This list is not exhaustive.
Is Tesamorelin + Ipamorelin legal?
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Components: Tesamorelin FDA-approved; Ipamorelin not..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.